Medical device firm Sonavex has received clearance from the U.S. Food and Drug Administration (FDA) to market its EchoMark and EchoMark Low Profile (LP) soft-tissue markers for ultrasound scans.
The markers are echogenic, resorbable polymeric implants used with ultrasound for marking soft-tissue sites in surgical patients. They are Sonavex's first products to receive FDA clearance, the company said.
In March, Sonavex secured $4.5 million in financing, which it plans to use for its EchoMark marketing efforts. Based in Baltimore, the company is a spin-off of Johns Hopkins.
